Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | PDE6D | O43924 | 1/20 | 0.54 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.52 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | AKT1 | P31749 | 2/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28860507 | 0.86 | HMGCR (0.56) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL431291 | 0.86 | HMGCR (0.55) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL6804623 | 0.86 | HMGCR (0.55) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL2219461 | 0.85 | HMGCR (0.62) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL14403869 | 0.85 | HMGCR (0.56) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL2341001 | 0.85 | HMGCR (0.54) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL2339006 | 0.85 | HMGCR (0.54) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL2347371 | 0.85 | HMGCR (0.54) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL3445256 | 0.84 | HMGCR (0.56) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL29482554 | 0.84 | HMGCR (0.58) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9850213-B2 | Method for preparing rosuvastatin sodium | JIANGXI BOYA SEEHOT PHARMACEUTICAL CO., LTD. (CN) | 2017-12-26 | — | — | US | claimed |
| US-20170183314-A1 | METHOD FOR PREPARING ROSUVASTATIN SODIUM | FUDAN UNIVERSITY (CN) | 2017-06-29 | — | — | US | claimed |
| US-9850213-B2 | Method for preparing rosuvastatin sodium | JIANGXI BOYA SEEHOT PHARMACEUTICAL CO., LTD. (CN) | 2017-12-26 | — | — | US | disclosed |
| US-20170183314-A1 | METHOD FOR PREPARING ROSUVASTATIN SODIUM | FUDAN UNIVERSITY (CN) | 2017-06-29 | — | — | US | disclosed |
| CN-104829600-A | Synthesis process of intermediate for rosuvastatin synthesis | ZHEJIANG NEO DANKONG PHARMACEUTICAL CO LTD | 2015-08-12 | — | — | CN | disclosed |
| CN-101277966-B | Process for the synthesis of HMG-CoA reductase inhibitors | LEK PHARMACEUTICALS | 2013-03-27 | — | — | CN | disclosed |
| CN-101277966-A | Process for the synthesis of HMG-CoA reductase inhibitors | LEK PHARMACEUTICALS (SI) | 2008-10-01 | — | — | CN | disclosed |
| EP-1904456-A1 | PROCESSES FOR THE MANUFACTURE OF ROSUVASTATIN AND INTERMEDIATES | AstraZeneca UK Limited (GB) | 2008-04-02 | — | — | EP | disclosed |
| EP-1871747-A2 | PROCESS FOR PREPARING ROSUVASTATIN | AstraZeneca UK Limited (GB) | 2008-01-02 | — | — | EP | disclosed |
| WO-2007007119-A1 | PROCESSES FOR THE MANUFACTURE OF ROSUVASTATIN AND INTERMEDIATES | ASTRAZENECA UK LIMITED (GB) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006067456-A2 | PROCESS FOR PREPARING ROSUVASTATIN | ASTRAZENECA UK LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183314-A1 | METHOD FOR PREPARING ROSUVASTATIN SODIUM | HMGCR, NOX4, PTEN | HMGCR 1/4885ALDH1A1 1238/4885CYP3A4 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.